Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Titan Files NDA for Slow-Release Anti-Opioid Probuphine

Washington Drug Letter

Nov. 5, 2012 | Vol. 44 No. 44

Titan Files NDA for Slow-Release Anti-Opioid Probuphine

Titan Pharmaceutical has submitted an NDA seeking priority review of its Probuphine subcutaneous implant to treat adult opioid dependence.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Briefs Drug Industry Seeks Clarity on FDA Biosimilar User Fees FDA Decision on Cordran Provides Lifeline for IGI Labs CorePharma Wants Investigation Into Endo’s Moban Withdrawal

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.